General Information of Disease (ID: DIS0BYVV)

Disease Name Uterine cervix neoplasm
Synonyms
cervix; tumour of the cervix uteri; cervical tumor; uterine cervix tumor; cervical tumour; tumour of the cervix; neoplasm of cervix uteri; neoplasm of the uterine cervix; tumour of cervix uteri; neoplasm of the cervix uteri; cervix uteri tumor; tumor of the cervix uteri; tumor of uterine cervix; cervix tumour; cervix uteri neoplasm; tumour of uterine cervix; neoplasm of the cervix; cervix uteri tumour; neoplasm of uterine cervix; uterine cervix neoplasm (disease); tumor of the cervix; tumour of the uterine cervix; uterine cervix tumour; cervix tumor; neoplasm of cervix; tumor of the uterine cervix; cervix neoplasm; tumor of cervix; tumor of cervix uteri; tumour of cervix; Cervical neoplasm
Definition A neoplasm (disease) that involves the uterine cervix.
Disease Hierarchy
DIS5Z2HI: Tumor of uterus
DISTBY9Z: Tumour
DIS1HG31: Cervix disorder
DIS0BYVV: Uterine cervix neoplasm
Disease Identifiers
MONDO ID
MONDO_0021230
MESH ID
D002583
UMLS CUI
C0007873
MedGen ID
40201
HPO ID
HP:0032241
SNOMED CT ID
123841004

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 25 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
CASP8 TT6SZNG Limited Biomarker [1]
CCND1 TTFCJ7S Limited Biomarker [2]
RARB TTISP28 Limited Biomarker [3]
CTNNB1 TTRPKQG moderate Genetic Variation [4]
BIRC5 TTTPU1G Strong Biomarker [2]
CREBBP TTFRCTK Strong Genetic Variation [4]
EP300 TTGH73N Strong Genetic Variation [4]
ERBB3 TTSINU2 Strong Genetic Variation [4]
FANCF TTNZKFJ Strong Posttranslational Modification [5]
FBXW7 TT29KY7 Strong Genetic Variation [4]
FGFR3 TTST7KB Strong Genetic Variation [6]
HRAS TT28ZON Strong Genetic Variation [4]
JAK2 TTRMX3V Strong Biomarker [7]
KRAS TTM8FR7 Strong Genetic Variation [8]
MTHFR TTQWOU1 Strong Biomarker [9]
MTOR TTCJG29 Strong Genetic Variation [4]
MYC TTNQ5ZP Strong Biomarker [2]
NOTCH1 TTB1STW Strong Biomarker [10]
NOTCH2 TT82FVD Strong Biomarker [10]
RHCG TTN5MZ3 Strong Altered Expression [11]
STAT3 TTHJT3X Strong Biomarker [12]
TERT TTQY2EJ Strong Biomarker [13]
UCHL3 TT23UD6 Strong Altered Expression [14]
UCHL5 TTSX29Z Strong Altered Expression [14]
WNT5A TTKG7F8 Strong Biomarker [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 25 DTT(s)
This Disease Is Related to 16 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
APOBEC3B OTHLNI51 Limited Biomarker [15]
CLPTM1L OTDJWQXI Limited Biomarker [13]
CYLD OT37FKH0 Limited Biomarker [16]
ERCC1 OTNPYQHI Limited Biomarker [17]
HLA-DPB1 OTW8JHU2 Limited Biomarker [18]
POU4F1 OTMHYGWQ Limited Biomarker [19]
B4GALT2 OTYIQT2F Strong Biomarker [20]
DLG1 OTCRZYWT Strong Altered Expression [21]
HES1 OT8P19W2 Strong Biomarker [10]
MMP20 OT16S5S3 Strong Altered Expression [22]
PAX1 OT0Y3MIM Strong Biomarker [23]
PIAS3 OT3TWH9R Strong Biomarker [10]
PRSS50 OTC5JAVO Strong Genetic Variation [24]
SOX1 OTVI1RAR Strong Biomarker [25]
SRSF2 OTVDHO6U Strong Biomarker [26]
TSPAN1 OTZQPIYK Strong Altered Expression [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 DOT(s)

References

1 A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers.Nat Genet. 2007 May;39(5):605-13. doi: 10.1038/ng2030. Epub 2007 Apr 22.
2 PIAS3, SHP2 and SOCS3 Expression patterns in Cervical Cancers: Relevance with activation and resveratrol-caused inactivation of STAT3 signaling.Gynecol Oncol. 2015 Dec;139(3):529-35. doi: 10.1016/j.ygyno.2015.09.087. Epub 2015 Oct 4.
3 [Relationship between RAR-beta gene expression defect and its methylation].Zhonghua Fu Chan Ke Za Zhi. 2007 Jul;42(7):472-6.
4 Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.Nat Biotechnol. 2016 Feb;34(2):155-63. doi: 10.1038/nbt.3391. Epub 2015 Nov 30.
5 Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.Cancer Res. 2004 May 1;64(9):2994-7. doi: 10.1158/0008-5472.can-04-0245.
6 Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.Hum Mol Genet. 2005 May 1;14(9):1153-60. doi: 10.1093/hmg/ddi127. Epub 2005 Mar 16.
7 The effect of quercetin nanoparticle on cervical cancer progression by inducing apoptosis, autophagy and anti-proliferation via JAK2 suppression. Biomed Pharmacother. 2016 Aug;82:595-605. doi: 10.1016/j.biopha.2016.05.029. Epub 2016 Jun 9.
8 Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.Cancer Med. 2015 Oct;4(10):1484-93. doi: 10.1002/cam4.492. Epub 2015 Jul 8.
9 Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition. 2007 Mar;23(3):229-35. doi: 10.1016/j.nut.2006.12.006. Epub 2007 Feb 14.
10 Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. Genes Cancer. 2014 May;5(5-6):154-64. doi: 10.18632/genesandcancer.15.
11 RHCG suppresses cervical cancer progression through inhibiting migration and inducing apoptosis regulated by TGF-1.Biochem Biophys Res Commun. 2018 Sep 3;503(1):86-93. doi: 10.1016/j.bbrc.2018.05.183. Epub 2018 Jun 11.
12 GRIM?19?mediated Stat3 activation is a determinant for resveratrol?induced proliferation and cytotoxicity in cervical tumor?derived cell lines. Mol Med Rep. 2015 Feb;11(2):1272-7. doi: 10.3892/mmr.2014.2797. Epub 2014 Oct 29.
13 Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.Nat Genet. 2009 Feb;41(2):221-7. doi: 10.1038/ng.296. Epub 2009 Jan 18.
14 Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines.Mol Carcinog. 2006 Apr;45(4):260-9. doi: 10.1002/mc.20177.
15 Evidence for APOBEC3B mutagenesis in multiple human cancers.Nat Genet. 2013 Sep;45(9):977-83. doi: 10.1038/ng.2701. Epub 2013 Jul 14.
16 miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD.Chem Biol Interact. 2018 Apr 1;285:85-95. doi: 10.1016/j.cbi.2018.02.024. Epub 2018 Feb 23.
17 Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.Radiother Oncol. 2010 Nov;97(2):352-9. doi: 10.1016/j.radonc.2010.08.019. Epub 2010 Oct 9.
18 A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12.Nat Genet. 2013 Aug;45(8):918-22. doi: 10.1038/ng.2687. Epub 2013 Jun 30.
19 Molecular analysis of oncogenicity of the transcription factor, BRN3A, in cervical cancer cells.J Cancer Res Clin Oncol. 2011 Dec;137(12):1859-67. doi: 10.1007/s00432-011-1059-0. Epub 2011 Sep 18.
20 beta4GalT-II increases cisplatin-induced apoptosis in HeLa cells depending on its Golgi localization.Biochem Biophys Res Commun. 2007 Jun 22;358(1):41-6. doi: 10.1016/j.bbrc.2007.04.044. Epub 2007 Apr 18.
21 Differential expression of the human homologue of drosophila discs large oncosuppressor in histologic samples from human papillomavirus-associated lesions as a marker for progression to malignancy.Int J Cancer. 2004 Sep 1;111(3):373-80. doi: 10.1002/ijc.20275.
22 Survey of dentin sialophosphoprotein and its cognate matrix metalloproteinase-20 in human cancers.Cancer Med. 2019 May;8(5):2167-2178. doi: 10.1002/cam4.2117. Epub 2019 Apr 1.
23 Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results.Am J Obstet Gynecol. 2011 Jan;204(1):21.e1-7. doi: 10.1016/j.ajog.2010.07.036. Epub 2010 Sep 15.
24 TSP50 depends on its threonine protease activity and its interactions with TNF--induced NF-B for its role in human cervical tumorigenesis.Cell Biochem Biophys. 2015 Mar;71(2):891-6. doi: 10.1007/s12013-014-0279-8.
25 Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm.BMC Cancer. 2015 May 19;15:418. doi: 10.1186/s12885-015-1411-x.
26 Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).J Virol. 2015 May;89(10):5276-87. doi: 10.1128/JVI.03434-14. Epub 2015 Feb 25.
27 Identification of a new proliferation-associated protein NET-1/C4.8 characteristic for a subset of high-grade cervical intraepithelial neoplasia and cervical carcinomas.Int J Cancer. 2002 Jun 20;99(6):771-5. doi: 10.1002/ijc.10442.